HARROW INC (HROW)
US4158581094 - Common Stock
Taking everything into account, HROW scores 4 out of 10 in our fundamental rating. HROW was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of HROW have multiple concerns. HROW is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year HROW has reported negative net income.
In the past year HROW had a positive cash flow from operations.
In the past 5 years HROW reported 4 times negative net income.
Of the past 5 years HROW 4 years had a positive operating cash flow.
1.2 Ratios
HROW's Return On Assets of -9.50% is fine compared to the rest of the industry. HROW outperforms 70.00% of its industry peers.
The Return On Equity of HROW (-57.62%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.5% | ||
| ROE | -57.62% | ||
| ROIC | N/A |
ROA(3y)-11.86%
ROA(5y)-8.23%
ROE(3y)-83.03%
ROE(5y)-52.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of HROW has declined.
HROW has a better Gross Margin (72.56%) than 77.89% of its industry peers.
In the last couple of years the Gross Margin of HROW has grown nicely.
The Profit Margin and Operating Margin are not available for HROW so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.56% |
OM growth 3Y-25.96%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.41%
GM growth 5Y2.98%
2. Health
2.1 Basic Checks
HROW does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HROW has been increased compared to 1 year ago.
Compared to 5 years ago, HROW has more shares outstanding
Compared to 1 year ago, HROW has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.44 indicates that HROW is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.44, HROW is in the better half of the industry, outperforming 71.58% of the companies in the same industry.
The Debt to FCF ratio of HROW is 60.96, which is on the high side as it means it would take HROW, 60.96 years of fcf income to pay off all of its debts.
HROW's Debt to FCF ratio of 60.96 is fine compared to the rest of the industry. HROW outperforms 76.32% of its industry peers.
HROW has a Debt/Equity ratio of 3.21. This is a high value indicating a heavy dependency on external financing.
HROW has a worse Debt to Equity ratio (3.21) than 84.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.21 | ||
| Debt/FCF | 60.96 | ||
| Altman-Z | 2.44 |
ROIC/WACCN/A
WACC10.32%
2.3 Liquidity
HROW has a Current Ratio of 1.55. This is a normal value and indicates that HROW is financially healthy and should not expect problems in meeting its short term obligations.
HROW has a Current ratio of 1.55. This is in the lower half of the industry: HROW underperforms 70.53% of its industry peers.
A Quick Ratio of 1.44 indicates that HROW should not have too much problems paying its short term obligations.
HROW's Quick ratio of 1.44 is on the low side compared to the rest of the industry. HROW is outperformed by 66.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
The earnings per share for HROW have decreased strongly by -106.67% in the last year.
HROW shows a strong growth in Revenue. In the last year, the Revenue has grown by 48.15%.
Measured over the past years, HROW shows a very strong growth in Revenue. The Revenue has been growing by 25.77% on average per year.
EPS 1Y (TTM)-106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
Revenue 1Y (TTM)48.15%
Revenue growth 3Y38.63%
Revenue growth 5Y25.77%
Sales Q2Q%43.75%
3.2 Future
HROW is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 74.53% yearly.
The Revenue is expected to grow by 52.09% on average over the next years. This is a very strong growth
EPS Next Y9.34%
EPS Next 2Y66.7%
EPS Next 3Y72.77%
EPS Next 5Y74.53%
Revenue Next Year45.69%
Revenue Next 2Y46.72%
Revenue Next 3Y48.07%
Revenue Next 5Y52.09%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HROW. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 59.12, HROW can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, HROW is valued a bit cheaper than the industry average as 74.21% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.73, HROW is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 59.12 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HROW is valued a bit cheaper than the industry average as 74.21% of the companies are valued more expensively.
HROW's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. HROW is cheaper than 76.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 397.52 | ||
| EV/EBITDA | 391.77 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HROW does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as HROW's earnings are expected to grow with 72.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.7%
EPS Next 3Y72.77%
5. Dividend
5.1 Amount
No dividends for HROW!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HARROW INC
NASDAQ:HROW (12/23/2024, 12:01:55 PM)
34.07
-0.15 (-0.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners54.62%
Inst Owner Change9%
Ins Owners14.01%
Ins Owner Change1.08%
Market Cap1.21B
Analysts84
Price Target57.94 (70.06%)
Short Float %9.32%
Short Ratio5.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-56.71%
Min EPS beat(2)-127.34%
Max EPS beat(2)13.92%
EPS beat(4)1
Avg EPS beat(4)-162.09%
Min EPS beat(4)-448.69%
Max EPS beat(4)13.92%
EPS beat(8)2
Avg EPS beat(8)-190.39%
EPS beat(12)3
Avg EPS beat(12)-1204.53%
EPS beat(16)5
Avg EPS beat(16)-976.5%
Revenue beat(2)1
Avg Revenue beat(2)2.16%
Min Revenue beat(2)-8.55%
Max Revenue beat(2)12.87%
Revenue beat(4)1
Avg Revenue beat(4)-2.04%
Min Revenue beat(4)-8.55%
Max Revenue beat(4)12.87%
Revenue beat(8)3
Avg Revenue beat(8)-2.27%
Revenue beat(12)6
Avg Revenue beat(12)-0.36%
Revenue beat(16)9
Avg Revenue beat(16)1.32%
PT rev (1m)-6.66%
PT rev (3m)22.94%
EPS NQ rev (1m)-15.74%
EPS NQ rev (3m)36.98%
EPS NY rev (1m)-57.54%
EPS NY rev (3m)-20.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.32%
Revenue NY rev (1m)-5.17%
Revenue NY rev (3m)-1.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 59.12 | ||
| P/S | 7.17 | ||
| P/FCF | 397.52 | ||
| P/OCF | 283.66 | ||
| P/B | 20.93 | ||
| P/tB | N/A | ||
| EV/EBITDA | 391.77 |
EPS(TTM)-0.93
EYN/A
EPS(NY)0.58
Fwd EY1.69%
FCF(TTM)0.09
FCFY0.25%
OCF(TTM)0.12
OCFY0.35%
SpS4.75
BVpS1.63
TBVpS-3.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.5% | ||
| ROE | -57.62% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.56% | ||
| FCFM | 1.8% |
ROA(3y)-11.86%
ROA(5y)-8.23%
ROE(3y)-83.03%
ROE(5y)-52.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.27%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-25.96%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.41%
GM growth 5Y2.98%
F-Score6
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.21 | ||
| Debt/FCF | 60.96 | ||
| Debt/EBITDA | 54.72 | ||
| Cap/Depr | 10.23% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 125.79% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 2.44 |
F-Score6
WACC10.32%
ROIC/WACCN/A
Cap/Depr(3y)497.93%
Cap/Depr(5y)320.82%
Cap/Sales(3y)40.85%
Cap/Sales(5y)25.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
EPS Next Y9.34%
EPS Next 2Y66.7%
EPS Next 3Y72.77%
EPS Next 5Y74.53%
Revenue 1Y (TTM)48.15%
Revenue growth 3Y38.63%
Revenue growth 5Y25.77%
Sales Q2Q%43.75%
Revenue Next Year45.69%
Revenue Next 2Y46.72%
Revenue Next 3Y48.07%
Revenue Next 5Y52.09%
EBIT growth 1Y-343.52%
EBIT growth 3Y2.64%
EBIT growth 5YN/A
EBIT Next Year316.31%
EBIT Next 3Y181.63%
EBIT Next 5Y140.5%
FCF growth 1Y47.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.83%
OCF growth 3YN/A
OCF growth 5Y40.96%